ClinicalTrials.gg
Not yet recruitingNCT07789015VERANDA™-IIMUpdated Nov 13, 2026

A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies

A Phase 3 interventional study of Placebo and Nerandomilast in Idiopathic Inflammatory Myopathies, sponsored by Boehringer Ingelheim. Not yet recruiting at 160 sites in 26 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Updated Nov 13, 2026First sites in Czechia and United KingdomStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
270
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 78 studies in Myositis with a site in United States — 26 open to participants now, 32 under way, 6 of them phase 3. Myositis · United States.

Planned enrollment
5th of 56
270 · median 34
Started
2026
with 7 others
Phase 3
4 of 78
3 open now
Primary completion
2030-03
later than 24 of 29 live
Registered
75th of 78
by date

Among the 78 studies in Myositis with a site in United States, this one is the 5th largest by planned enrollment of the 56 interventional ones that give a count, is one of 8 that started in 2026, is one of 4 in phase 3, reaches primary completion later than 24 of the 29 other live ones, and was the 75th registered.

Myositis

215 studies on the registry are indexed under Myositis; 100 are open to participants now.

Browse Myositis studies →

Open to participants now

26 of the 78 studies in Myositis with a site in United States are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 71 Myositis studies recruiting now, 27 (38%) set no upper age limit and 36 (51%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in Myositis with a site in United States, or all of them as a file.
02

Study summary

This study is open to adults aged 18 and older who have a condition known as active idiopathic inflammatory myopathy (IIM) or myositis. People can participate if they have a specific type of myositis. The purpose of this study is to find out whether a medicine called nerandomilast improves IIM symptoms.

Participants are put into 2 groups randomly, which means by chance. One group takes nerandomilast tablets and the other group takes placebo tablets. Placebo tablets look like nerandomilast tablets but do not contain any medicine. Participants take nerandomilast or placebo twice a day for 1 year.

Participants are in the study for about 1 year and 2 months. During this time, they visit the study site at least 16 times. During this time, doctors regularly check the participant's health, IIM symptoms, and take note of any unwanted effects. Participants fill in questionnaires about their IIM symptoms and how IIM impacts their quality of life. The results are compared between the 2 groups to see whether the treatment works.

03

Conditions studied

  • Idiopathic Inflammatory Myopathies

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female adult individuals from ≥18 years of age (or alternative age for adults based on local regulations) on the date of signing the .
  2. A definite or probable clinical diagnosis of idiopathic inflammatory myopathy (IIM) according to the 2017 American college of rheumatology (ACR)/European alliance of associations of rheumatology (EULAR) classification criteria.
  3. Participants with overlap myositis (OM) must have IIM as the predominant disease.
  4. Participants ≥18 years of age (or alternative age for adults based on local regulations) with juvenile dermatomyositis (JDM) can only be included if they were 15 years old or older at first onset of DM symptoms.
  5. Disease activity defined by moderate to severe myopathy.
  6. The participant must be on background therapy for IIM.
  7. Woman (or women) of (WOCBP) must be ready and able to use highly effective methods of for a period of 28 days before treatment initiation, throughout the trial, and for a period of at least 5 days after the last dose of medicinal product (IMP). WOCBP taking oral contraceptives also have to use one barrier method.
  8. Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial. 9. Further inclusion criteria apply.

Exclusion criteria

Exclusion criteria:

  1. Major surgery (major according to the investigator's assessment, e.g. hip replacement) performed within 6 weeks prior to randomisation or planned during the trial period.
  2. Any documented active or suspected or history of malignancy within 5 years prior to screening, except appropriately treated basal cell carcinoma of the skin, or in situ squamous cell carcinoma of the skin, or in situ carcinoma of uterine cervix.
  3. Participants who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial.
  4. Participants diagnosed with advanced interstitial lung disease (ILD).
  5. Severe muscle damage.
  6. Further exclusion criteria apply.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
270 participants (estimated)

Study arms

  • Experimental
    Nerandomilast

    Drug: Nerandomilast

  • Placebo comparator
    Placebo

    Placebo matching nerandomilast

    Drug: Placebo

Interventions

  • DrugPlacebo

    Placebo-matching nerandomilast

  • Nerandomilast

06

What researchers measure

Primary outcomes

  1. Total improvement score (TIS) score (continuous) at Week 52

    The TIS composite score includes 6 core set measures: manual muscle testing (MMT8), extra-muscular disease activity (MDAAT), patient global disease activity (PtGA), physician global disease activity (PhGA), health assessment questionnaire disability index (HAQ-DI), and muscle enzymes. An improvement score for each core set measure will be assigned using the absolute percent change, based on predetermined ranges. The TIS will be the sum of the all core set measure, scoring from 0 to 100, with higher scores corresponding to a greater degree of improvement.

    Time frame: At Week 52.

Secondary outcomes

  1. Achievement of a TIS-40 response (yes/no; defined as TIS ≥40) at Week 52

    Number of participants with 40 TIS points or higher.

    Time frame: At Week 52.

  2. Achievement of a successful tapering of oral corticosteroids (OCS) (yes/no) at Week 52

    Number of participants achieving a TIS-40 response at Week 52 and ≤5 mg/day of prednisone (or equivalent) at Week 52

    Time frame: At Week 52.

  3. Change from baseline in cutaneous dermatomyositis disease area and severity index activity score (CDASI-A) at Week 52 (in participants with baseline CDASI-A ≥6)

    The Cutaneous Dermatomyositis Disease Area and Severity Index activity score (CDASI-A) is a questionnaire assessing skin disease activity and damage in patients with dermatomyositis (DM). It ranges from 0 to 100, with higher values indicating more severe active skin involvement.

    Time frame: At baseline and at Week 52.

  4. Change from baseline in extra-muscular disease activity as per myositis disease activity assessment tool (MDAAT) at Week 52

    Myositis Disease Activity Assessment Tool (MDAAT) is a questionnaire assessing the disease activity of extra-muscular organ systems and muscle in participants with IIM. It is a combined tool with two parallel scores: the MYOACT VAS and the MITAX. The Myositis disease activity assessment (MYOACT) visual analogue scale (VAS) scores the overall severity of disease activity. The sum of the individual scores ranges from 0 to 70, The higher the more severe. For the Myositis Intention-to-Treat Activity Index (MITAX), each question is answered with either: 0 = not present; 1 = improving; 2 = the same; 3 = worse; 4 = new. The summed scores are summed to obtain a total MITAX score with a range of 0 to 63, the higher the more severe.

    Time frame: At baseline and at Week 52.

  5. Change from baseline in PtGA at Week 52

    Patient global disease activity (PtGA) measures the participant's self-assessment of the disease. It is composed of a 100 mm visual analogue scale. Patients will mark their assessment between "extremely poor" (0) and "excellent" (100). The difference between 0 (extremely poor) and the patient assessment is the PtGA, where higher distances indicate a better health status.

    Time frame: At baseline and at Week 52.

  6. Change from baseline in clinical-reported outcome 1 at Week 12

    Time frame: At baseline and at Week 12.

  7. Change from baseline in PhGA at Week 52

    Physician global activity (PhGA) captures the physician's assessment of the participant's overall health. It is composed of a 100 mm visual analogue scale. Physicians will mark their assessment between "extremely poor" (0) and "excellent" (100). The difference between 0 (extremely poor) and the physician assessment is the PhGA, where higher distances indicate a better health status.

    Time frame: At baseline and at Week 52.

  8. Change from baseline in HAQ-DI at Week 52

    The health assessment questionnaire disability index (HAQ-DI) assesses difficulties in performing activities of daily living across 8 domains. Each domain is rated on a scale of 0-3. The higher the score, the higher the disability.

    Time frame: At baseline and at Week 52.

  9. Change from baseline in MMT-8 score at Week 52

    Manual Muscle Testing (MMT-8) assesses the muscle strength of 8 proximal, distal, and axial muscle groups. Each item is rated from 0 to 10, with the total score ranging from 0 to 150, where higher scores mean better muscle strength condition.

    Time frame: At baseline and at Week 52.

  10. Achievement of a TIS-60 response (yes/no; defined as TIS ≥60) at Week 52

    Time frame: At baseline and at Week 52.

  11. Change from baseline in clinical-reported outcome 2 at Week 12

    Time frame: At baseline and at Week 12.

  12. Change from baseline in the most abnormal baseline muscle enzymes (aldolase, CK, AST, ALT, or LDH) at Week 52

    CK means creatine kinase, AST means aspartate aminotransferase, ALT means alanine aminotransferase, and LDH means lactate dehydrogenase.

    Time frame: At baseline and at Week 52.

07

Study locations

160 sites

Showing the first 100 of 160 sites across 26 countries. Choose a country and city above to see the rest.

08

References and documents

Related links

Individual participant data

Plan to share: Yes — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing

Time frame: One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.

Access criteria: For study documents -upon signing of a 'Document Sharing Agreement'. For study data -1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.

Data sharing details ↗ · www.clinicalstudies.boehringer-ingelheim.com

09

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Dec 2026; primary completion for Mar 2030, 39 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: start Nov 2026 → Dec 2026 and completion Mar 2030 → Apr 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2026
First posted
Aug 27, 2026
StartEst.
Dec 14, 2026was Nov 2026
Primary completionEst.
Mar 21, 2030
CompletionEst.
Apr 4, 2030was Mar 2030
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
21 sites added, 8 sites removed — first sites in Czechia and United Kingdom
Show 21 added (8 United Kingdom, 5 United States, 2 Canada, 2 Australia, 2 Brazil, 1 Czechia, 1 Portugal)
  • University of Pittsburgh Medical Center · Pittsburgh, United States
  • Gordon & Leslie Diamond Health Care Centre (UBC) · Vancouver, Canada
  • Campbelltown Hospital · Campbelltown, Australia
  • Perron Institute · Nedlands, Australia
  • Hospital das Clinicas da Faculdade de Medicina da USP · São Paulo, Brazil
  • A2Z Clinical Centro Avançado de Pesquisa Clinica · Valinhos, Brazil
  • University of Calgary · Calgary, Canada
  • Revmatologicky Ustav · Prague, Czechia
  • City Health Campus · Birmingham, United Kingdom
  • Southmead Hospital · Bristol, United Kingdom
  • Doncaster Royal Infirmary · Doncaster, United Kingdom
  • Western General Hospital · Edinburgh, United Kingdom
  • Northwick Park Hospital · Harrow, United Kingdom
  • Aintree University Hospital · Liverpool, United Kingdom
  • Salford Royal Hospital · Salford, United Kingdom
  • New Cross Hospital · Wolverhampton, United Kingdom
  • The University of Chicago Medical Center · Chicago, United States
  • Oregon Health & Sciences University · Portland, United States
  • Penn State Milton S. Hershey Medical Center · Hershey, United States
  • The University of Texas Health Science Center at Houston · Houston, United States
  • ULS de Santa Maria, E.P.E - Hospital de Santa Maria · Lisbon, Portugal
Show 8 removed
  • Heuer M.D. Research, Inc · Orlando, United States
  • Hospital das Clínicas da Faculdade de Medicina da USP · São Paulo, Brazil
  • Azidus Centro de Pesquisa Clinica Avancada · Valinhos, Brazil
  • South Health Campus (Calgary) · Calgary, Canada
  • Universitätsklinikum Ulm · Ulm, Germany
  • Arizona Neuromuscular Research Center · Phoenix, United States
  • Oregon Health and Sciences University · Portland, United States
  • ULS de Santa Maria, E.P.E · Lisbon, Portugal
across 4 updates, Sep 30, 2026 – Nov 13, 2026
Start date
Nov 9, 2026→Dec 14, 2026
Oct 14, 2026
Study completion
Mar 26, 2030→Apr 4, 2030
Oct 14, 2026
Show all 4 updates
  1. Nov 13, 2026
    5 sites added, 3 sites removed
    Show 5 added (4 United States, 1 Portugal)
    • The University of Chicago Medical Center · Chicago, United States
    • Oregon Health & Sciences University · Portland, United States
    • Penn State Milton S. Hershey Medical Center · Hershey, United States
    • The University of Texas Health Science Center at Houston · Houston, United States
    • ULS de Santa Maria, E.P.E - Hospital de Santa Maria · Lisbon, Portugal
    Show 3 removed
    • Arizona Neuromuscular Research Center · Phoenix, United States
    • Oregon Health and Sciences University · Portland, United States
    • ULS de Santa Maria, E.P.E · Lisbon, Portugal
    + 1 other change: verification date
  2. Oct 29, 2026
    9 sites added, 1 site removed — first sites in Czechia and United Kingdom
    Show 9 added (8 United Kingdom, 1 Czechia)
    • Revmatologicky Ustav · Prague, Czechia
    • City Health Campus · Birmingham, United Kingdom
    • Southmead Hospital · Bristol, United Kingdom
    • Doncaster Royal Infirmary · Doncaster, United Kingdom
    • Western General Hospital · Edinburgh, United Kingdom
    • Northwick Park Hospital · Harrow, United Kingdom
    • Aintree University Hospital · Liverpool, United Kingdom
    • Salford Royal Hospital · Salford, United Kingdom
    • New Cross Hospital · Wolverhampton, United Kingdom
    Show 1 removed
    • Universitätsklinikum Ulm · Ulm, Germany
  3. Oct 14, 2026
    5 sites added, 4 sites removed
    Show 5 added (2 Australia, 2 Brazil, 1 Canada)
    • Campbelltown Hospital · Campbelltown, Australia
    • Perron Institute · Nedlands, Australia
    • Hospital das Clinicas da Faculdade de Medicina da USP · São Paulo, Brazil
    • A2Z Clinical Centro Avançado de Pesquisa Clinica · Valinhos, Brazil
    • University of Calgary · Calgary, Canada
    Show 4 removed
    • Heuer M.D. Research, Inc · Orlando, United States
    • Hospital das Clínicas da Faculdade de Medicina da USP · São Paulo, Brazil
    • Azidus Centro de Pesquisa Clinica Avancada · Valinhos, Brazil
    • South Health Campus (Calgary) · Calgary, Canada
    Start date Nov 9, 2026→Dec 14, 2026
    Study completion Mar 26, 2030→Apr 4, 2030
    + 1 other change: verification date
  4. Sep 30, 2026
    2 sites added
    Show 2 added (1 United States, 1 Canada)
    • University of Pittsburgh Medical Center · Pittsburgh, United States
    • Gordon & Leslie Diamond Health Care Centre (UBC) · Vancouver, Canada

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07789015
Responsible party
Sponsor
First posted
Aug 27, 2026
Start date
Dec 14, 2026 (estimated)
Primary completion
Mar 21, 2030 (estimated)
Completion
Apr 4, 2030 (estimated)
Last update
Nov 13, 2026

Study contacts

Boehringer Ingelheim
Contact
clintriage.rdg@boehringer-ingelheim.com
1-800-243-0127

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nerandomilast

Start the discussion